TDOC:NYE-Teladoc Inc. (USD)

EQUITY | Health Information Services | New York Stock Exchange

Last Closing

USD 13.01

Change

-0.32 (-2.40)%

Market Cap

USD 0.81B

Volume

7.70M

Analyst Target

USD 241.46
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Teladoc Inc provides telehealth platform, delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
VEEV Veeva Systems Inc Class A

+2.17 (+1.07%)

USD 32.00B
SOLV Solventum Corp.

+0.87 (+1.34%)

USD 11.73B
DOCS Doximity Inc

-0.23 (-0.93%)

USD 4.83B
EVH Evolent Health Inc

+0.37 (+1.36%)

USD 3.36B
AGTI Agiliti Inc

N/A

USD 1.37B
PHR Phreesia Inc

-0.08 (-0.35%)

USD 1.16B
MPLN MultiPlan Corporation

-0.02 (-2.46%)

USD 0.43B
AMWL American Well Corp

-0.01 (-2.18%)

USD 0.17B
OWLT Owlet Inc

-0.35 (-7.87%)

USD 0.03B
FOXO FOXO Technologies Inc.

N/A

USD 3.00M

ETFs Containing TDOC

RWM ProShares Short Russell20.. 0.00 % 0.95 %

-0.05 (0%)

USD 0.21B
CCON 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.63% 27% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.63% 27% F 3% F
Trailing 12 Months  
Capital Gain -50.96% 27% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.96% 27% F 4% F
Trailing 5 Years  
Capital Gain -77.47% 25% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.47% 25% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 4.08% 64% D 56% F
Dividend Return 4.08% 64% D 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.58% 18% F 7% C-
Risk Adjusted Return 4.09% 64% D 30% F
Market Capitalization 0.81B 67% D+ 65% D

Key Financial Ratios

  Ratio vs. Industry/Classification (Health Information Services) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1.03 75% 69%
Price / Cash Flow Ratio 6.28 50% 54%
Price/Free Cash Flow Ratio 18.67 33% 17%
Management Effectiveness  
Return on Equity -9.51% 50% 18%
Return on Invested Capital -6.47% 33% 14%
Return on Assets -3.01% 42% 14%
Debt to Equity Ratio 66.15% 57% 50%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.